{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:22:52Z","timestamp":1791404572468,"version":"4.3.3"},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R56AG052949"],"award-info":[{"award-number":["R56AG052949"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AG024968"],"award-info":[{"award-number":["P30AG024968"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>In June 2017, a diverse group of experts in Alzheimer's disease convened to discuss how to accelerate getting new drugs to patients to both prevent and treat the disease. Participants concluded that we need a more robust, diversified drug development pipeline. Strategic policy measures can help keep new Alzheimer's disease therapies (whether to treat symptoms, prevent onset, or cure) affordable for patients while supporting innovation and facilitating greater information sharing among payers, providers, researchers, and the public, including a postmarket surveillance study system, disease registries, innovative payment approaches, harmonizing federal agency review requirements, allowing conditional coverage for promising therapeutics and technology while additional data are collected, and opening up channels for drug companies to communicate with payers (and each other) about data and outcomes. To combat reimbursement issues, policy makers should address the latency time between potential treatment\u2014which may be costly and fall on private payers\u2014and societal benefits that accrue elsewhere.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.jalz.2018.02.007","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T08:46:07Z","timestamp":1524041167000},"page":"833-836","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Accelerating Alzheimer's disease drug innovations from the research pipeline to patients"],"prefix":"10.1002","volume":"14","author":[{"given":"Dana P.","family":"Goldman","sequence":"first","affiliation":[{"name":"Public Policy, Pharmacy, and Economics University of Southern California Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Fillit","sequence":"additional","affiliation":[{"name":"Founding Executive Director and Chief Science Officer Alzheimer's Drug Discovery Foundation New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Neumann","sequence":"additional","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health Institute for Clinical Research and Health Policy Studies Tufts Medical Center Tufts University School of Medicine Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"key":"e_1_2_3_2_2","volume-title":"Eli Lilly's Experimental Drug Fails in Large Trial","author":"Belluck P","year":"2016"},{"key":"e_1_2_3_3_2","volume-title":"J&J Scrap Alzheimer's Studies as Drug Fails","author":"Pfizer BB","year":"2012"},{"key":"e_1_2_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.01.004"},{"key":"e_1_2_3_5_2","doi-asserted-by":"publisher","DOI":"10.1515\/fhep-2014-0013"},{"key":"e_1_2_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-4580(92)90030-2"},{"key":"e_1_2_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2017.05.002"},{"key":"e_1_2_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.03.001"},{"key":"e_1_2_3_9_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2013.1314"},{"key":"e_1_2_3_10_2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3233\/JAD-2010-091606","article-title":"Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer\u2010type dementia: implications for trial design","volume":"20","author":"Rossum IA","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"e_1_2_3_11_2","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.5698"},{"key":"e_1_2_3_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004073"},{"key":"e_1_2_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.04.011"},{"key":"e_1_2_3_14_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1215\/03616878-4249796","article-title":"Innovative contracting for pharmaceuticals and Medicaid's best\u2010price rule","volume":"43","author":"Sachs RE","year":"2018","journal-title":"J Health Polit Policy Law"},{"key":"e_1_2_3_15_2","volume-title":"Dementia: A Public Health Priority","author":"World Health Organization and Alzheimer's Disease International","year":"2012"},{"key":"e_1_2_3_16_2","doi-asserted-by":"publisher","DOI":"10.1503\/jpn.140355"},{"key":"e_1_2_3_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5205"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526018300505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526018300505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.jalz.2018.02.007","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2018.02.007","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1016\/j.jalz.2018.02.007","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2018.02.007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T21:12:19Z","timestamp":1759871539000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1016\/j.jalz.2018.02.007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1016\/j.jalz.2018.02.007"],"URL":"https:\/\/doi.org\/10.1016\/j.jalz.2018.02.007","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,18]]},"assertion":[{"value":"2018-04-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}